Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.
July 17, 2023 | 2:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Silence Therapeutics and maintained a $20 price target.
The reiteration of an Overweight rating by Morgan Stanley indicates a positive outlook for Silence Therapeutics. The maintained price target of $20 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100